When a biotech drug trial hits 100% response rates, you typically want to check the fine print. But Roivant Sciences (ROIV) investors weren't nitpicking on Friday, sending shares up over 20% to a new 52-week high after the company announced surprisingly strong Phase 2 results for brepocitinib in cutaneous sarcoidosis.
Cutaneous sarcoidosis is an inflammatory skin condition characterized by small bumps and raised lesions that can be particularly stubborn to treat. The BEACON study enrolled 31 patients split across three groups: once-daily brepocitinib at 45 mg, 15 mg, or placebo, with everyone treated for 16 weeks.
The Treatment-Resistant Patients Responded Best
Here's where it gets interesting. The 45 mg group included the toughest cases—patients with the longest disease duration, the most tissue damage, and the difficult-to-treat plaque-predominant morphology. These weren't easy wins. Yet this group achieved meaningful clinical improvement across the board, including 100% response rates on multiple endpoints.
The lower 15 mg dose also showed considerable improvements, with similar results to the higher dose on easier-to-reach benchmarks. On more challenging endpoints and patient-reported outcomes, the data suggested clear dose-dependent benefits. Meanwhile, placebo patients saw almost no improvement, which tracks with how this disease typically progresses without treatment.
The numbers tell a compelling story. On the Cutaneous Sarcoidosis Activity and Morphology Instrument Activity score (CSAMI-A), brepocitinib 45 mg delivered a 22.3-point mean improvement at Week 16 versus just 0.7 points for placebo. The separation showed up as early as Week 4 and stuck around through every measurement after that.
Every single patient in the 45 mg group—100%—achieved at least a 10-point improvement on CSAMI-A, compared to just 14% of placebo patients. Even more impressively, 62% of brepocitinib 45 mg patients hit CSAMI-A scores below 5, which represents functional remission. Not one placebo patient reached that threshold.
Gold Standard Results With Clean Safety Profile
On the Investigator's Global Assessment, 69% of brepocitinib 45 mg patients achieved the gold standard two-point improvement to Clear or Almost Clear status, versus 0% of placebo patients. That 69 percentage point difference carried statistical significance (P=.0047).
Patient-reported outcomes backed up what doctors were seeing. On the Patient Global Impression of Change, 100% of patients taking the 45 mg dose reported improvement from baseline, compared to 29% of placebo patients—a 71 percentage point difference with strong statistical significance (P=.0014).
The safety profile looks clean. No serious adverse events occurred during the study, and all adverse events were graded mild or moderate. That's critical for a drug targeting a chronic condition where patients might need long-term treatment.
Roivant's subsidiary Priovant plans to advance cutaneous sarcoidosis into a Phase 3 pivotal program starting in 2026, following discussions with the FDA. This would mark the third indication with a pivotal program for brepocitinib.
Meanwhile, Another Trial Fills Up
In related news, Roivant's subsidiary Pulmovant completed enrollment in its Phase 2 PHocus trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease. Topline data should arrive in the second half of 2026.
On the earnings front, Roivant reported an adjusted loss of 24 cents per share, beating the consensus estimate of a 32-cent loss. Sales came in around $2 million. The company ended December with $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities—enough runway to support operations into profitability.
Price Action: Roivant Sciences shares traded up 20.03% at $25.37 on Friday, hitting a new 52-week high.
